Date: 2017-08-24
Type of information: Collaboration agreement
Compound: imaging technologies, including ultrasound and radiolabeled imaging, to improve the diagnosis and management of joint disease in people with hemophilia
Company: Bioverativ (USA - MA) Invicro (USA - MA)
Therapeutic area: Rare diseases - Genetic diseases - Hematological diseases - Diagnosis
Type agreement: collaboration
Action mechanism:
Disease: joint disease in people with hemophilia
Details:
- • On August 24, 2017, Bioverativ and Invicro, a provider of imaging services and analysis for pharmaceutical research and development, today announced that they have formed a strategic collaboration focused on expanding the use and adoption of leading imaging technologies, including ultrasound and radiolabeled imaging, to improve the diagnosis and management of joint disease in people with hemophilia.
- One of the primary focuses of this imaging collaboration will be to investigate the impact of Bioverativ’s leading extended half-life therapies, Eloctate® [Antihemophilic Factor (Recombinant), Fc Fusion] and Alprolix® [Coagulation Factor IX (Recombinant), Fc Fusion Protein], and its investigational therapy BIVV001 [VWF-XTEN-rFcFVIII], on protection from bleeds and improvement of long-term joint health in people with hemophilia.
- This alliance focuses on the novel application of radiolabeled imaging technology to Alprolix® and other factor IX therapies, to study the importance of factor IX distribution to tissue and its role in improving joint health, which may lead to better patient outcomes. Bioverativ expects to present data from this preclinical study at an upcoming scientific congress.
- This collaboration will also focus on advancing the use of ultrasound imaging in the diagnosis and monitoring of joint disease in people with hemophilia as clinical examinations lack the ability to discriminate joint bleeding from other joint conditions.
- Additionally, Bioverativ and Invicro will develop standardized protocols to monitor and assess joint health using musculoskeletal ultrasound imaging in people with hemophilia in research studies of their marketed and pipeline products and in clinical practice. Invicro will serve as the ultrasound imaging contract research organization for the clinical studies. Together, the companies plan to establish a path for the integration of the ultrasound methodologies in hemophilia clinical practice in the future.
Financial terms:
Latest news:
Is general: Yes
